PlasmidFactory obtained worldwide license from DKFZ for manufacture of pDG helper/packaging vectors

16-Feb-2007

PlasmidFactory has obtained a worldwide license from the German Cancer Research Center DKFZ for the manufacture and the marketing of the pDG helper/packaging vector series used for adeno-associated virus (AAV) production.

The license agreement extends to multiple vector serotypes such as pDG, pDM, and pDP1rs to pDP6rs as well as the pDG without heparin binding motive and other helper/packaging vectors. PlasmidFactory, who manufactures these vectors in stock for immediate shipment, is furthermore allowed to issue sub-licenses to other distributors to assure efficient and worldwide sales and distribution.

Other news from the department science

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Last viewed contents

A type of virus present in the gut microbiota is associated with better cognitive ability in humans, mice and flies - The study finds a greater presence of these viruses in people who eat dairy products in their regular diet

A type of virus present in the gut microbiota is associated with better cognitive ability in humans, mice and flies - The study finds a greater presence of these viruses in people who eat dairy products in their regular diet

Study in Spain and Romania confirms radon as second leading cause of lung cancer

Xenomics Names Research Oncologist and Biotechnology Executive Dr. David Sidransky to Board of Directors

Sartorius closes acquisition of selected assets of Danaher Life Sciences - Broadens portfolio for the development and production of biotech medicines

Sartorius closes acquisition of selected assets of Danaher Life Sciences - Broadens portfolio for the development and production of biotech medicines

EMA starts rolling review of COVID-19 vaccine Vidprevtyn - Protein-based vaccine developed by Sanofi Pasteur

EMA starts rolling review of COVID-19 vaccine Vidprevtyn - Protein-based vaccine developed by Sanofi Pasteur

Researchers use sugar to halt esophageal cancer in its tracks

Anika Therapeutics Announces Termination of Worldwide Development and Commercialization Partnership with OrthoNeutrogena - Company Files Pre-Market Approval Applicaton for Cosmetic Tissue Augmentation Product

Scottish Life Sciences Sector set to Benefit from South Korean Institute Opening in Glasgow

Endotis Pharma forms a strategic alliance with Catalent Pharma Solutions for the development of synthetic oligosaccharides

MedMira Reaches Funding Agreement to Enable US Market Expansion

Oral Multi-Kinase Inhibitor SB1317, Enters Phase 1 Clinical Trial in Advanced/Refractory Hematologic Malignancies

Abbott and Biotest Announce Global Agreement to Develop and Commercialize Novel Antibody for Autoimmune Diseases - BT-061 in clinical development for the treatment of RA and psoriasis